Payment overview · 2025
General Payments
$482.21
24 reported records · 10 companies
Healthcare provider profile · identity verified
Michael S Strobbe, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · PORT RICHEY, FL · NPI 1437125002
Verified facts
What the public records show
CMS Open Payments records show Michael S Strobbe, D.O. received $482.21 in general payments during 2025 across 24 reported records.
PFIZER INC. accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.36 | 17.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $85.24 | 17.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $83.30 | 17.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.77 | 13.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.01 | 11.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.56 | 6.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.47 | 5.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.99 | 3.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.84 | 3.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.67 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $482.21 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.24 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $85.24 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $83.30 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.57 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $59.57 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.01 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.66 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $17.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 127 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 224 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 49 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 129 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
96 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
127 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
64 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
129 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
224 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
280 | 86 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 920 | 301 |
| Lisinopril | Lisinopril | 734 | 238 |
| Alprazolam | Alprazolam | 718 | 134 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 659 | 149 |
| Pantoprazole Sodium | Pantoprazole Sodium | 636 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 603 | 200 |
| Levothyroxine Sodium | Levothyroxine Sodium | 593 | 179 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 570 | 184 |
| Losartan Potassium | Losartan Potassium | 535 | 181 |
| Furosemide | Furosemide | 513 | 164 |
| Gabapentin | Gabapentin | 511 | 169 |
| Omeprazole | Omeprazole | 435 | 140 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 397 | 129 |
| Metformin Hcl | Metformin Hcl | 387 | 130 |
| Metoprolol Succinate | Metoprolol Succinate | 364 | 133 |
| Methylprednisolone | Methylprednisolone | 349 | 274 |
| Prednisone | Prednisone | 334 | 179 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 330 | 63 |
| Clonazepam | Clonazepam | 327 | 63 |
| Tramadol Hcl | Tramadol Hcl | 311 | 104 |
| Clopidogrel | Clopidogrel Bisulfate | 302 | 98 |
| Tamsulosin Hcl | Tamsulosin Hcl | 290 | 98 |
| Eliquis | Apixaban | 280 | 86 |
| Trazodone Hcl | Trazodone Hcl | 262 | 89 |
| Doxycycline Hyclate | Doxycycline Hyclate | 244 | 176 |
| Azithromycin | Azithromycin | 242 | 197 |
| Meloxicam | Meloxicam | 226 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 225 | 71 |
| Ozempic | Semaglutide | 224 | 53 |
| Temazepam | Temazepam | 218 | 47 |
| Simvastatin | Simvastatin | 210 | 69 |
| Potassium Chloride | Potassium Chloride | 206 | 66 |
| Montelukast Sodium | Montelukast Sodium | 203 | 73 |
| Famotidine | Famotidine | 200 | 78 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 194 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 182 | 65 |
| Pregabalin | Pregabalin | 180 | 42 |
| Sertraline Hcl | Sertraline Hcl | 174 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 168 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 32 |
| Carvedilol | Carvedilol | 157 | 53 |
| Diclofenac Sodium | Diclofenac Sodium | 157 | 67 |
| Celecoxib | Celecoxib | 145 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 140 | 44 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 139 | 49 |
| Cefdinir | Cefdinir | 138 | 111 |
| Jardiance | Empagliflozin | 131 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 129 | 42 |
| Farxiga | Dapagliflozin Propanediol | 127 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 122 | 93 |
| Ondansetron Hcl | Ondansetron Hcl | 119 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 39 |
| Aripiprazole | Aripiprazole | 112 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 111 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 110 | 31 |
| Spironolactone | Spironolactone | 103 | 37 |
| Diazepam | Diazepam | 102 | 26 |
| Linzess | Linaclotide | 96 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 25 |
| Levetiracetam | Levetiracetam | 92 | 23 |
| Lorazepam | Lorazepam | 92 | 19 |
| Nystatin | Nystatin | 92 | 41 |
| Ventolin Hfa | Albuterol Sulfate | 92 | 54 |
| Glimepiride | Glimepiride | 91 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 28 |
| Clonidine Hcl | Clonidine Hcl | 85 | 30 |
| Atenolol | Atenolol | 82 | 26 |
| Metformin Hcl Er | Metformin Hcl | 80 | 29 |
| Allopurinol | Allopurinol | 77 | 28 |
| Buspirone Hcl | Buspirone Hcl | 77 | 28 |
| Meclizine Hcl | Meclizine Hcl | 77 | 38 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 77 | 29 |
| Donepezil Hcl | Donepezil Hcl | 75 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 72 | 26 |
| Sucralfate | Sucralfate | 72 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 71 | 18 |
| Mirtazapine | Mirtazapine | 71 | 26 |
| Baclofen | Baclofen | 70 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 70 | 14 |
| Xarelto | Rivaroxaban | 69 | 21 |
| Fenofibrate | Fenofibrate | 68 | 21 |
| Solifenacin Succinate | Solifenacin Succinate | 68 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 21 |
| Methocarbamol | Methocarbamol | 65 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 64 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 43 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 37 |
| Ibuprofen | Ibuprofen | 60 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 22 |
| Alendronate Sodium | Alendronate Sodium | 59 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 59 | 13 |
| Fluconazole | Fluconazole | 57 | 35 |
| Tresiba Flextouch U-200 | Insulin Degludec | 56 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 17 |
| Finasteride | Finasteride | 54 | 16 |
| Trulicity | Dulaglutide | 54 | suppressed |
| Metronidazole | Metronidazole | 53 | 39 |
| Warfarin Sodium | Warfarin Sodium | 53 | 17 |
| Glipizide | Glipizide | 52 | 17 |
| Primidone | Primidone | 52 | 15 |
| Propranolol Hcl | Propranolol Hcl | 52 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 16 |
| Mounjaro | Tirzepatide | 49 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 16 |
| Rybelsus | Semaglutide | 49 | 11 |
| Metolazone | Metolazone | 48 | 16 |
| Ondansetron Odt | Ondansetron | 47 | 17 |
| Synthroid | Levothyroxine Sodium | 46 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | 12 |
| Bupropion Xl | Bupropion Hcl | 45 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 16 |
| Valacyclovir | Valacyclovir Hcl | 44 | 16 |
| Ezetimibe | Ezetimibe | 43 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 13 |
| Cephalexin | Cephalexin | 42 | 32 |
| Amiodarone Hcl | Amiodarone Hcl | 41 | 16 |
| Midodrine Hcl | Midodrine Hcl | 41 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | 13 |
| Azelastine Hcl | Azelastine Hcl | 40 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 40 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 13 |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 12 |
| Klor-Con 10 | Potassium Chloride | 38 | 17 |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 24 |
| Topiramate | Topiramate | 37 | 14 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | 11 |
| Estradiol | Estradiol | 34 | 11 |
| Glipizide Er | Glipizide | 34 | 12 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Sotalol | Sotalol Hcl | 34 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 34 | 12 |
| Bumetanide | Bumetanide | 33 | 12 |
| Dofetilide | Dofetilide | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 33 | suppressed |
| Valsartan | Valsartan | 33 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 32 | 25 |
| Mupirocin | Mupirocin | 32 | 23 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 22 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 30 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 14 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | 16 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 14 |
| Ramipril | Ramipril | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 20 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 20 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 20 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Acetazolamide | Acetazolamide | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Rinvoq | Upadacitinib | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Codeine Sulfate | Codeine Sulfate | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $482.21 · 24 records | PFIZER INC. | Dexcom G6 Transmitter, FARXIGA, INSPIRE, Kerendia, NURTEC ODT, Ozempic, PROCLAIM, QULIPTA, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, Wegovy, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error